Hyperbaric Oxygen in the Prevention of Radiation Pneumonitis

Status Recruiting

Clinical Trial Summary

Radiotherapy is one of the important treatments to improve the survival rate of breast cancer patients, but also has the risk of radiation lung injury, which can develop into pulmonary fibrosis. Hyperbaric oxygen can improve the tissue after radiation by promoting the function of vascular endothelial cells and fibroblasts, and reducing the secretion of inflammatory factors, thereby inhibiting the process of fibrosis and fiber atrophy after radiotherapy, and promoting tissue repair. Therefore, it has the potential value of treating chronic radiation injury. We aim to investigate whether hyperbaric oxygen treatment can reduce the incidence of radiation pneumonia and improve patients' quality of life, and to evaluate its safety and the impact on the patients' long-term survival outcomes.

Clinical Trial Description

Radiotherapy is one of the important treatments to improve the survival rate of breast cancer patients. Radiotherapy also has the risk of radiation lung injury, which can develop into pulmonary fibrosis, which seriously affects the quality of life of patients. Hyperbaric oxygen has received more attention in the field of delayed tissue damage caused by radiotherapy. In a hyperbaric oxygen environment, sufficient oxygen supply can improve the tissue after radiation by promoting the function of vascular endothelial cells and fibroblasts, and reducing the secretion of inflammatory factors. Low blood vessel density, low cell activity and low oxygen content in the "three low" state, thereby inhibiting the process of fibrosis and fiber atrophy after radiotherapy, and promoting tissue repair. Therefore, it has the potential value of treating chronic radiation injury. Can hyperbaric oxygen therapy be applied for breast cancer patients who were receiving radiotherapy, reduce the risk of radiation pneumonitis, prevent radiation pneumonitis and even radiofibrosis, and improve long-term survival? Therefore, we plan to prospectively enroll 380 breast cancer patients and randomly divide them into two groups. The treatment group will be given 30-40 hyperbaric oxygen therapy immediately after the end of radiotherapy, to study whether hyperbaric oxygen therapy reduces the risk of radiation pneumonia, and to evaluate hyperbaric oxygen The safety of treatment and its impact on the patient's quality of life and long-term survival outcomes provide an effective means to reduce the incidence of radiation pneumonia and improve the long-term quality of life. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05189496
Study type	Interventional
Source	Guangdong Provincial People's Hospital
Contact	Kun Wang
Phone	13922118086
Email	gzwangkun@126.com
Status	Recruiting
Phase	N/A
Start date	March 1, 2022
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02490319` - Study on the Biological Prediction Models of Radiation Pneumonitis
Recruiting	`NCT03803787` - Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients	Phase 2
Completed	`NCT03796364` - Clinical Study of Endostatin in Improving Radiation Pneumonia and Fibrosis	Phase 2
Not yet recruiting	`NCT04632342` - Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 on Radiation Pneumonitis in Non-small Cell Lung Cancer Patients	Phase 2
Recruiting	`NCT05365802` - FAPI PET for Lung Fibrosis	Early Phase 1
Completed	`NCT01754909` - Mitigation of Radiation Pneumonitis and Fibrosis	Phase 2
Completed	`NCT01745484` - Role of SPECT in Radiotherapy of Lung Cancer and Toxicity Evaluation	N/A
Enrolling by invitation	`NCT02809456` - Mitigation of Radiation Pneumonitis, Fibrosis and Heart Toxicity With Nicorandil in Lung Cancer Patients	Phase 2
Recruiting	`NCT00155909` - Risk Factors of Radiation Pneumonitis	N/A
Recruiting	`NCT06069115` - Radiotherapy Exposed Lung Injury: Effect on Functioning - Cohort
Not yet recruiting	`NCT02296281` - Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury	Phase 2
Completed	`NCT04863027` - Use of Dual Energy Computed Tomography in Thoracic Radiotherapy Planning.
Completed	`NCT03462524` - Neoadjuvant Therapy for Esophageal Cancer and Cardiopulmonary Physiology	N/A
Recruiting	`NCT05448703` - A Study on Predictive Models and Clinical Outcome of Radiation Pneumonitis
Recruiting	`NCT06079931` - The Efficacy of Babaodan Capsules in Preventing Radiation Pneumonia	Phase 2
Recruiting	`NCT04676828` - Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer	N/A
Recruiting	`NCT02735746` - Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.